Supplemental Figure 3: HSPGs, EGFR, and HBEGF associate to promote neuroblast differentiation. A) Western blot for differentiation markers following treatment with 10ng/ml sTβRIII or 100ng/ml sSDC3 or sGPC1 in the presence or absence of 0.5ng/mL HBEGF. Densitometry for NF160 normalized to β-actin is shown as the percentage of control. B) ERBB receptor expression in benign neuroblastic tumors (ganglioneuroma/ganglioneuroblastoma) or neuroblastoma (NB) tumors in the microarray meta-dataset (only GSE12460, GSE16237, GSE13141 were included in analysis due to unshared probe for EGFR), Kruskal-Wallis: p<0.0001, Mann-Whitney for intergroup comparisons: **p<0.01, ***p<0.001. Bold text indicates HBEGF receptor. C) EGFR expression in neuroblastoma patients by stage. Kruskal-Wallis: p<0.0001, Mann-Whitney for intergroup comparisons: **p<0.01, ****p<0.0001. D) Event-free survival in NB with low (bottom 50%; red) and high (top 50%; blue) *EGFR* expression in the GSE49710 dataset. E) Co-immunoprecipitation in COS-7 following 72 hour HBEGF treatment with additional 5 minute HBEGF treatment prior to lysis. F) Linear regression analyses using the indicated datasets. Box plots are presented as median (horizontal bars) and interquartile range (boxes).